Neuroone Medical Technologies Corp. (NMTC) intrinsic value & 10-year financials
Neuroone Medical Technologies Corp. (NMTC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 167.3% a year to $9.1M, with an average return on invested capital of -1041.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.96
- Market cap
- $38.6M
- Revenue (FY2025)
- $9.1M
- Revenue growth (10-yr CAGR)
- 167.3%
- ROIC (10-yr avg)
- -1041.9%
- Free cash flow (FY2025)
- -$2.9M
NMTC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $9.1M | -$3.6M | -$0.09 | -$2.9M | -46.5% | -3575.9% |
| FY2024 | $3.5M | -$12.3M | -$0.46 | -$11.1M | -344.3% | -4574.5% |
| FY2023 | $2.0M | -$11.9M | -$0.65 | -$13.3M | -612.3% | -931.7% |
| FY2022 | $171.2K | -$10.0M | -$0.63 | -$7.8M | -5860.2% | -1409.3% |
| FY2021 | $178.1K | -$9.9M | -$0.93 | -$8.7M | -5735.9% | 1069.3% |
| FY2020 | — | -$13.6M | — | -$3.5M | — | 794.9% |
| FY2019 | — | -$6.8M | — | -$5.5M | — | 240.7% |
| FY2018 | — | — | — | — | — | — |
| FY2017 | — | — | — | — | — | — |
| FY2016 | $0 | -$47.8K | — | — | — | 51.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NEUROONE MEDICAL TECHNOLOGIES Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NEUROONE MEDICAL TECHNOLOGIES Corp has historically struggled to out-earn its cost of capital, averaging just -4.1% ROIC.
NEUROONE MEDICAL TECHNOLOGIES Corp has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NEUROONE MEDICAL TECHNOLOGIES Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.99 per share.